200,000+ products from a single source!
sales@angenechem.com
Home > Imidazoles > 2010-15-3
2010-15-3 | 4-Imidazolidinone, 3-phenyl-2-thioxo-
CAS No: 2010-15-3 Catalog No: AG002D57 MDL No:MFCD00027413
Product Description
Catalog Number:
AG002D57
Chemical Name:
4-Imidazolidinone, 3-phenyl-2-thioxo-
CAS Number:
2010-15-3
Molecular Formula:
C9H8N2OS
Molecular Weight:
192.2376
MDL Number:
MFCD00027413
IUPAC Name:
3-phenyl-2-sulfanylideneimidazolidin-4-one
InChI:
InChI=1S/C9H8N2OS/c12-8-6-10-9(13)11(8)7-4-2-1-3-5-7/h1-5H,6H2,(H,10,13)
InChI Key:
ZZRIQDWDJVLELF-UHFFFAOYSA-N
SMILES:
O=C1CNC(=S)N1c1ccccc1
EC Number:
217-927-3
Properties
Complexity:
236
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
192.036g/mol
Formal Charge:
0
Heavy Atom Count:
13
Hydrogen Bond Acceptor Count:
2
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
192.236g/mol
Monoisotopic Mass:
192.036g/mol
Rotatable Bond Count:
1
Topological Polar Surface Area:
64.4A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
1.4
Literature
| Title | Journal |
|---|---|
| Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. | The New England journal of medicine 20180628 |
| Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. | The Prostate 20150901 |
| Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. | Nucleic acids research 20150713 |
| Enzalutamide in metastatic prostate cancer before chemotherapy. | The New England journal of medicine 20140731 |
| Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20140615 |
| Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC). | BMC urology 20140101 |
| NF-κB2/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. | Molecular cancer therapeutics 20130801 |
| Management of docetaxel failures in metastatic castrate-resistant prostate cancer. | The Urologic clinics of North America 20121101 |
| Increased survival with enzalutamide in prostate cancer after chemotherapy. | The New England journal of medicine 20120927 |
| Enzalutamide--a major advance in the treatment of metastatic prostate cancer. | The New England journal of medicine 20120927 |
| Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. | BJU international 20120901 |
| Urologists and oncologists: adapting to a new treatment paradigm in castration-resistant prostate cancer (CRPC). | BJU international 20120801 |
| Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. | Cancer research 20120715 |
| Novel molecular targets for the therapy of castration-resistant prostate cancer. | European urology 20120501 |
| The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer. | Current opinion in oncology 20120501 |
| Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. | Cancer research 20120501 |
| Beyond castration-defining future directions in the hormonal treatment of prostate cancer. | Hormones & cancer 20120401 |
| ARN-509: a novel antiandrogen for prostate cancer treatment. | Cancer research 20120315 |
| MDV3100 for the treatment of prostate cancer. | Expert opinion on investigational drugs 20120201 |
| The evolution of antiandrogens: MDV3100 comes of age. | Expert review of anticancer therapy 20120201 |
| Novel therapies for metastatic castrate-resistant prostate cancer. | Journal of the National Cancer Institute 20111116 |
| Current clinical trials in castrate-resistant prostate cancer. | Current urology reports 20110601 |
| [The trend toward development of novel agents based on the mechanism of prostate cancer progression]. | Nihon rinsho. Japanese journal of clinical medicine 20110601 |
| Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells. | Molecular and cellular endocrinology 20110101 |
| Changing therapeutic paradigms in castrate-resistant prostate cancer. | Clinical genitourinary cancer 20101201 |
| A renaissance in the medical treatment of advanced prostate cancer. | Oncology (Williston Park, N.Y.) 20101201 |
| Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. | Bioorganic & medicinal chemistry letters 20101101 |
| Revisiting the ultimate target of treatment for prostate cancer. | Lancet (London, England) 20100424 |
| Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. | Lancet (London, England) 20100424 |
| [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives]. | Urologia 20100101 |
| Steroid hormone receptors in prostate cancer: a hard habit to break? | Cancer cell 20091208 |
| Beyond castration and chemotherapy: novel approaches to targeting androgen-driven pathways. | Maturitas 20091020 |
| New therapeutic agents for castration-refractory prostate cancer. | Clinical genitourinary cancer 20090801 |
| Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer. | Cancer cell 20090602 |
| Development of a second-generation antiandrogen for treatment of advanced prostate cancer. | Science (New York, N.Y.) 20090508 |
| Drug development. New way to target hormone receptor thwarts prostate cancer. | Science (New York, N.Y.) 20090410 |
| Electrochemical analysis of the alanine phenylthiohydantoin derivative by cathodic stripping voltammetry. | Analytical biochemistry 20080801 |
| Polymeric alkenoxy amino acid surfactants: V. Comparison of carboxylate and sulfate head group polymeric surfactants for enantioseparation in MEKC. | Electrophoresis 20070601 |
| ABRF ESRG 2005 study: identification of seven modified amino acids by Edman sequencing. | Journal of biomolecular techniques : JBT 20061201 |
| Immobilization of phospholipid-avidin on fused-silica capillaries for chiral separation in open-tubular capillary electrochromatography. | Electrophoresis 20060401 |
| Substituted 2-thioxoimidazolidin-4-ones and imidazolidine-2,4-diones as fatty acid amide hydrolase inhibitors templates. | Journal of medicinal chemistry 20060112 |
| Simultaneous optimization of the resolution and analysis time in micellar liquid chromatography of phenyl thiohydantoin amino acids using Derringer's desirability function. | Journal of chromatography. A 20050617 |
| Inactivation of brain myo-inositol monophosphate phosphatase by pyridoxal-5'-phosphate. | Journal of biochemistry and molecular biology 20050131 |
| Enantioselectivity of structurally modified poly(sodium undecenoyl-L-leucinate) by insertion of Triton X-102 surfactant molecules. | Electrophoresis 20040801 |
| Separation of phenylthiohydantoin amino acids by capillary electrochromatography. | Electrophoresis 20040201 |
| Identification of PTH-amino acids by HPLC. | Methods in molecular biology (Clifton, N.J.) 20030101 |
| Rapid separation of phenylthiohydantoin amino acids: ambient pressure ion-mobility mass spectrometry (IMMS). | Analytical and bioanalytical chemistry 20030101 |
| Applicability of a modified Edman procedure for measurement of protein adducts: mechanisms of formation and degradation of phenylthiohydantoins. | Chemical research in toxicology 20020401 |
| Separation of barbiturates and phenylthiohydantoin amino acids using the thermally tuned tandem column concept. | Analytical chemistry 20010415 |
| Assignment of the disulfide bonds of huwentoxin-II by Edman degradation sequencing and stepwise thiol modification. | European journal of biochemistry 20010401 |
| Evaluation of anti-HIV activity of 5-(2-phenyl-3'-indolal)-2-thiohydantoin. | Farmaco (Societa chimica italiana : 1989) 19980730 |
| S-glucosylated hydantoins as new antiviral agents. | Journal of medicinal chemistry 19940107 |
| Amino acid sequences of a-factor mating peptides from Saccharomyces cerevisiae. | The Journal of biological chemistry 19870115 |
| Porcine pancreatic lipase. The disulfide bridges and the sulfhydryl groups. | European journal of biochemistry 19821115 |
| Amino acid sequence of heat-stable enterotoxin produced by Escherichia coli pathogenic for man. | The Journal of biological chemistry 19810810 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.